Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS ...

Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and ...

A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline. Among those surveyed, 83 percent ...

We started the company 17 years ago with the goal of helping cancer patients live longer and longer until they eventually outlive their disease. We can transform cancer into something that's more of a ...